ResMed Inc. (NYSE:RMD) insider James Hollingshead sold 600 shares of the firm’s stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $112.09, for a total value of $67,254.00. Following the completion of the sale, the insider now owns 83,689 shares in the company, valued at $9,380,700.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
James Hollingshead also recently made the following trade(s):
- On Tuesday, November 27th, James Hollingshead sold 5,893 shares of ResMed stock. The shares were sold at an average price of $105.52, for a total value of $621,829.36.
- On Thursday, November 1st, James Hollingshead sold 600 shares of ResMed stock. The shares were sold at an average price of $105.93, for a total value of $63,558.00.
- On Monday, October 1st, James Hollingshead sold 600 shares of ResMed stock. The shares were sold at an average price of $115.88, for a total value of $69,528.00.
Shares of RMD opened at $109.99 on Friday. The firm has a market cap of $16.01 billion, a PE ratio of 31.16, a price-to-earnings-growth ratio of 2.87 and a beta of 1.01. The company has a current ratio of 2.58, a quick ratio of 1.91 and a debt-to-equity ratio of 0.27. ResMed Inc. has a one year low of $83.88 and a one year high of $116.64.
ResMed (NYSE:RMD) last issued its quarterly earnings results on Thursday, October 25th. The medical equipment provider reported $0.81 EPS for the quarter, beating analysts’ consensus estimates of $0.80 by $0.01. The company had revenue of $588.28 million for the quarter, compared to analyst estimates of $576.66 million. ResMed had a return on equity of 26.29% and a net margin of 13.94%. Sell-side analysts anticipate that ResMed Inc. will post 3.69 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 13th. Stockholders of record on Thursday, November 8th will be issued a dividend of $0.37 per share. This represents a $1.48 dividend on an annualized basis and a dividend yield of 1.35%. The ex-dividend date is Wednesday, November 7th. ResMed’s dividend payout ratio (DPR) is 41.93%.
A number of equities research analysts have issued reports on the company. BMO Capital Markets raised their target price on ResMed from $107.00 to $109.00 and gave the company a “market perform” rating in a research note on Friday, October 26th. Credit Suisse Group raised ResMed from a “neutral” rating to an “outperform” rating in a report on Friday, October 26th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $114.50.
Institutional investors and hedge funds have recently modified their holdings of the company. Morgan Stanley increased its holdings in shares of ResMed by 30.2% during the second quarter. Morgan Stanley now owns 966,736 shares of the medical equipment provider’s stock valued at $100,135,000 after purchasing an additional 223,963 shares during the period. Pillar Pacific Capital Management LLC increased its holdings in shares of ResMed by 1.6% during the third quarter. Pillar Pacific Capital Management LLC now owns 46,546 shares of the medical equipment provider’s stock valued at $5,368,000 after purchasing an additional 744 shares during the period. DNB Asset Management AS grew its holdings in ResMed by 17.9% during the third quarter. DNB Asset Management AS now owns 18,045 shares of the medical equipment provider’s stock worth $2,081,000 after acquiring an additional 2,745 shares during the period. Motley Fool Asset Management LLC grew its holdings in ResMed by 0.8% during the second quarter. Motley Fool Asset Management LLC now owns 202,522 shares of the medical equipment provider’s stock worth $20,977,000 after acquiring an additional 1,522 shares during the period. Finally, Stephens Investment Management Group LLC grew its holdings in ResMed by 1.0% during the second quarter. Stephens Investment Management Group LLC now owns 360,961 shares of the medical equipment provider’s stock worth $37,567,000 after acquiring an additional 3,463 shares during the period. 65.02% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.thelincolnianonline.com/2018/12/08/james-hollingshead-sells-600-shares-of-resmed-inc-rmd-stock.html.
ResMed Company Profile
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.